Additional modulation may involve liver-expressed antimicrobial peptide 2 (LEAP-2), which could exacerbate ghrelin resistance due to its association with obesity and metabolic syndrome, both recognized AD risk factors [302,303]. This evidence concerns the gene LEAP2 and obesity due to melanocortin 4 receptor deficiency.